Suppliers / Alchymars ICM SM

Alchymars ICM SM

India Updated 9 July 2026

Alchymars ICM SM is an API manufacturer based in India. It holds 4 active US drug master files across a filed portfolio of 4 molecules. Its most recent recorded inspection, by US FDA, closed on 4 December 2025 as OAI. Customs aggregates show $1.0M of exports covering 6 molecules to 2 destinations in 2025.

4
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
6 of 6 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 4 December 2025 OAI US FDA
  • 22 November 2022 VAI US FDA
  • 19 October 2018 OAI US FDA
  • 15 September 2017 OAI US FDA
  • 6 February 2015 VAI US FDA
  • 2 April 2012 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Chengalpattu District, India 3005216842

What they file, and where

Molecule Regulators Docs
Warfarin SFDA (Saudi Arabia), US FDA 2
Atovaquone US FDA 1
Clindamycin US FDA 1
Risedronic Acid US FDA 1

Also appears on these molecule pages

Atovaquone API Risedronic Acid API Warfarin API Clindamycin API

Scale

Year Revenue Exports Destinations
2026 YTD Not reported $260K 1
2025 Not reported $1.0M 2

Export figures are customs aggregates. We do not publish the identity of any buyer.

Questions about Alchymars ICM SM

Does Alchymars ICM SM hold a US DMF or a CEP?
Alchymars ICM SM holds 4 active US drug master files. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
Is Alchymars ICM SM FDA-registered?
One site operated by Alchymars ICM SM carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Alchymars ICM SM's last inspection go?
The most recent inspection on record closed on 4 December 2025 as OAI (Official Action Indicated, the worst classification: objectionable conditions were found and regulatory action was warranted). 6 inspections are on file, of which 3 closed as OAI.
Where does Alchymars ICM SM manufacture?
1 registered site is on record, in India (Chengalpattu District). Every site is listed on this page with the register it came from.
What does Alchymars ICM SM make?
4 molecules are on record against Alchymars ICM SM, including Warfarin, Atovaquone, Clindamycin and Risedronic Acid. Each links through to that molecule's full manufacturer list.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Alchymars ICM SM comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was OAI, on 4 December 2025.

Comparable suppliers

Ipca Laboratories shares 3 molecules Apitoria Pharma shares 2 molecules Matrix Pharmacorp shares 2 molecules Zydus Lifesciences shares 2 molecules Apotex shares 2 molecules

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
Customs aggregates
Export values, molecule and destination counts